Significant effort has been, and continues to be, devoted
to the development of novel kinase inhibitors through the
“fitting of structures to the ATP-binding sites”, and this
approach has been quite successful at producing structures
for clinical trials. In an alternative approach that did not
initially concentrate on the specifics of the ATP-binding site,
the Waldman group successfully utilized BIOS to search for
kinase inhibitors